Skip to Main Content

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Conditions

Other Skin

Phase III

What is the purpose of this trial?

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

  • Trial with
    Alliance for Clinical Trials in Oncology
  • Start Date
    06/10/2019
  • End Date
    10/30/2023

For more information about this study, contact:

Neta Shanwetter Levit

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/04/2020
  • Study HIC
    #2000025163